fispemifene

DRUG2 trials

Sponsors

QuatRx Pharmaceuticals Company, NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)

Conditions

Chronic Obstructive Pulmonary DiseaseErectile DysfunctionHypogonadismSecondary HypogonadismSexual Dysfunction

Phase 2

Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy

CompletedNCT01061970

QuatRx Pharmaceuticals CompanyChronic Obstructive Pulmonary Disease, Hypogonadism

Start: 2007-01-31End: 2007-10-31Target: 15Updated: 2010-02-03

Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)Erectile Dysfunction, Secondary Hypogonadism, Sexual Dysfunction

Start: 2015-05-31End: 2016-04-30Target: 160Updated: 2015-11-13